Paul Boyatzis - Valeant Pharmaceuticals Non-Executive Chairman of the Board
Chairman
Mr. Paul Boyatzis, B Bus, ASA, MSDIA, CPA, has served as NonExecutive Chairman of the Board of Ventnor Resources Ltd since September 24, 2010. He has 25 years of experience in the investment and equity markets and knowledge of public companies. He has assisted emerging companies raise funds both locally and from overseas institutional investors. He is a current member of the Australian Institute of Company Directors, the Securities and Derivative Industry Association and a member of the Certified Practising Accountants of Australia. since 2010.
| Tenure | 14 years |
| Professional Marks | CPA |
| Phone | 514-744-6792 |
| Web | http://www.valeant.com |
Valeant Pharmaceuticals Management Efficiency
The company has Return on Asset of 0.69 % which means that on every $100 spent on assets, it made $0.69 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (21.51) %, meaning that it generated no profit with money invested by stockholders. Valeant Pharmaceuticals' management efficiency ratios could be used to measure how well Valeant Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company has 25.27 B in debt with debt to equity (D/E) ratio of 558.6, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Valeant Pharmaceuticals has a current ratio of 1.16, demonstrating that it may not have the ability to pay its financial commitments when the payables are due. Debt can assist Valeant Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Valeant Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valeant Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valeant to invest in growth at high rates of return. When we think about Valeant Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Kornelis Storm | Anheuser Busch Inbev | 73 | |
| Carlos Solis | Compania Cervecerias Unidas | 63 | |
| Martin Barrington | Anheuser Busch Inbev | 68 | |
| John Nicolson | Compania Cervecerias Unidas | 61 | |
| Marc Busain | Compania Cervecerias Unidas | N/A | |
| Timothy Main | Jabil Circuit | 62 | |
| Thomas Dennis | FormFactor | 64 | |
| Mark Mondello | Jabil Circuit | 60 | |
| Bill Ronald | Fevertree Drinks Plc | 59 | |
| Andronico Craig | Compania Cervecerias Unidas | 66 | |
| Nick Caporella | National Beverage Corp | 88 | |
| William Ronald | Fevertree Drinks Plc | 62 | |
| Charles Rolls | Fevertree Drinks Plc | 60 | |
| Raymond Stata | Analog Devices | 90 | |
| Thomas Sansone | Jabil Circuit | 71 | |
Management Performance
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 |
Valeant Pharmaceuticals Leadership Team
Elected by the shareholders, the Valeant Pharmaceuticals' board of directors comprises two types of representatives: Valeant Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valeant. The board's role is to monitor Valeant Pharmaceuticals' management team and ensure that shareholders' interests are well served. Valeant Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valeant Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Ingram, Lead Independent Director | ||
| Sarah Kavanagh, Independent Director | ||
| Pavel Mirovsky, President of Valeant Europe and General Manager of Valeant Europe | ||
| William Humphries, Executive Vice President Company Group Chairman, Dermatology | ||
| Bruce Maluish, Managing Director, Executive Director | ||
| Norma Provencio, Independent Director | ||
| Richard DeSchutter, Independent Director | ||
| Anders Lonner, Director | ||
| Robert Hale, Director | ||
| Louis Yu, Chief Quality Officer, Global Quality | ||
| Howard Schiller, Interim CEO and Director | ||
| Paul Herendeen, CFO, Executive Vice President - Finance | ||
| Peter Pawlowitsch, Non-Executive Director | ||
| Amy Wechsler, Independent Director | ||
| Colleen Goggins, Independent Director | ||
| Robert Power, Independent Director | ||
| Mason Morfit, Independent Director | ||
| Sherri Wilkin, Chief Creative Officer | ||
| Robert Rosiello, CFO and Executive VP | ||
| Theo MelasKyriazi, Independent Director | ||
| Argeris Karabelas, Independent Director | ||
| William Ackman, Director | ||
| Fredric Eshelman, Independent Director | ||
| Laurie Little, Vice President - Investor Relations | ||
| Christina Ackermann, Executive Vice President General Counsel | ||
| Katharine Stevenson, Independent Director | ||
| Paul Boyatzis, Non-Executive Chairman of the Board | ||
| Ronald Farmer, Independent Director | ||
| Thomas Ross, Independent Director | ||
| Laizer Kornwasser, Executive VP and Company Group Chairman | ||
| Joseph Papa, Chairman of the Board, CEO | ||
| Ari Kellen, Executive VP and Company Group Chairman | ||
| John Geary, Company Secretary | ||
| Elif McDonald, Director, Investor Relations | ||
| Robert ChaiOnn, Executive Vice President General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director | ||
| John Paulson, Independent Director | ||
| Michael Pearson, Chairman, CEO and Director(Leave of absence) | ||
| Stephen Fraidin, Independent Director | ||
| Thomas Appio, Executive Vice President and Presidentident - Asia Pacific | ||
| Brian Stolz, Executive Vice President - Administration, Chief Human Capital Officer | ||
| Anne Whitaker, Executive Vice President | ||
| Russel Robertson, Independent Director |
Valeant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Valeant Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -21.51 | |||
| Return On Asset | 0.69 | |||
| Profit Margin | (10.65) % | |||
| Operating Margin | 5.01 % | |||
| Current Valuation | 32.38 B | |||
| Shares Outstanding | 349.3 M | |||
| Shares Owned By Insiders | 0.30 % | |||
| Shares Owned By Institutions | 51.10 % | |||
| Number Of Shares Shorted | 14.62 M | |||
| Price To Earning | 3.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Valeant Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Valeant Pharmaceuticals' short interest history, or implied volatility extrapolated from Valeant Pharmaceuticals options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Valeant Stock
If you are still planning to invest in Valeant Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Valeant Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |